Bivalirudin vs Thymosin Alpha-1
Overview
Bivalirudin is primarily a cardiovascular peptide, while Thymosin Alpha-1 is used for healing & recovery.
This page compares Bivalirudin and Thymosin Alpha-1 across their primary use, typical dosing, reported benefits and side effects, and U.S. regulatory status. For the full monograph on either compound — mechanism of action, clinical research, and references — follow the article links.
Side-by-side comparison
| Bivalirudin | Thymosin Alpha-1 | |
|---|---|---|
| Category | Cardiovascular | Healing & Recovery |
| Regulatory status (US) | FDA approved | Research use only |
| Typical dosage | 0.75 mg/kg IV bolus, then 1.75 mg/kg/h IV infusion | 1.6-3.2 mg |
| Frequency | Single procedural session: bolus immediately before PCI followed by continuous infusion during the procedure; optional post-procedural infusion for up to approximately 20 hours | twice-weekly |
| Reported benefits | Anticoagulation during PCI and PTCA, anticoagulation in HIT/HITTS patients undergoing PCI, reduced major bleeding versus heparin plus glycoprotein IIb/IIIa inhibitor, predictable pharmacokinetics without need for antithrombin cofactor, rapid offset of anticoagulation due to short half-life, inhibition of both circulating and clot-bound thrombin | Immune enhancement, antiviral properties, chronic infection support, cancer therapy adjunct |
| Reported side effects | Bleeding (most common, including access-site and retroperitoneal), acute stent thrombosis (early, within 24 hours), back pain, nausea, headache, hypotension, injection-site pain, hypersensitivity reactions, thrombocytopenia (rare) | Well-tolerated. Rare: injection site reactions, mild flu-like symptoms |
Key differences
Primary use. Bivalirudin is categorised under Cardiovascular, while Thymosin Alpha-1 falls under Healing & Recovery. Their differing categories mean they are usually chosen for different goals rather than as direct substitutes.
Regulatory status. Bivalirudin: FDA-approved. Thymosin Alpha-1: not FDA-approved; treated as a research compound.
Dosing. Bivalirudin is typically dosed at 0.75 mg/kg IV bolus, then 1.75 mg/kg/h IV infusion (Single procedural session: bolus immediately before PCI followed by continuous infusion during the procedure; optional post-procedural infusion for up to approximately 20 hours). Thymosin Alpha-1 is typically dosed at 1.6-3.2 mg (twice-weekly).
Can you stack them?
Some protocols combine peptides, but stacking Bivalirudin and Thymosin Alpha-1 has not been validated for safety or efficacy in controlled trials. Combining compounds can change their effects and risks. Nothing here is medical advice — consult a qualified healthcare provider before starting or combining any protocol.
Frequently asked questions
- What is the difference between Bivalirudin and Thymosin Alpha-1?
- Bivalirudin is primarily a cardiovascular peptide, while Thymosin Alpha-1 is used for healing & recovery. Bivalirudin is FDA-approved for one or more indications, whereas Thymosin Alpha-1 is not FDA-approved; generally classified as a research compound.
- What is Bivalirudin used for?
- FDA-approved synthetic peptide direct thrombin inhibitor used for anticoagulation during PCI, including in HIT patients.
- What is Thymosin Alpha-1 used for?
- Immune system support.
- Can you take Bivalirudin and Thymosin Alpha-1 together?
- Some users combine peptides within a single protocol, but stacking Bivalirudin and Thymosin Alpha-1 has not been established as safe or effective in controlled trials. Neither this comparison nor PeptideSciences101 is medical advice — consult a qualified healthcare provider before combining any compounds.
- Is Bivalirudin or Thymosin Alpha-1 FDA-approved?
- Bivalirudin is FDA-approved for one or more indications. Thymosin Alpha-1 is not FDA-approved; generally classified as a research compound.
Read the full articles
- Bivalirudin — full monograph: mechanism, research, dosing & references
- Thymosin Alpha-1 — full monograph: mechanism, research, dosing & references